Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 198

1.

Hypoxia and HIF-1 increase S100A8 and S100A9 expression in prostate cancer.

Grebhardt S, Veltkamp C, Ströbel P, Mayer D.

Int J Cancer. 2012 Dec 15;131(12):2785-94. doi: 10.1002/ijc.27591. Epub 2012 May 8.

2.

Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH.

Yun SJ, Yan C, Jeong P, Kang HW, Kim YH, Kim EA, Lee OJ, Kim WT, Moon SK, Kim IY, Choi YH, Kim WJ.

Ann Surg Oncol. 2015 Jul;22(7):2439-45. doi: 10.1245/s10434-014-4194-4. Epub 2014 Oct 28.

PMID:
25348783
3.

S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells.

Hermani A, De Servi B, Medunjanin S, Tessier PA, Mayer D.

Exp Cell Res. 2006 Jan 15;312(2):184-97. Epub 2005 Nov 17.

PMID:
16297907
4.

Prostaglandin E2 stimulates S100A8 expression by activating protein kinase A and CCAAT/enhancer-binding-protein-beta in prostate cancer cells.

Miao L, Grebhardt S, Shi J, Peipe I, Zhang J, Mayer D.

Int J Biochem Cell Biol. 2012 Nov;44(11):1919-28. doi: 10.1016/j.biocel.2012.06.015. Epub 2012 Jun 20.

PMID:
22728165
5.

Impact of S100A8/A9 expression on prostate cancer progression in vitro and in vivo.

Grebhardt S, Müller-Decker K, Bestvater F, Hershfinkel M, Mayer D.

J Cell Physiol. 2014 May;229(5):661-71. doi: 10.1002/jcp.24489.

PMID:
24122301
6.

S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast.

Arai K, Takano S, Teratani T, Ito Y, Yamada T, Nozawa R.

Curr Cancer Drug Targets. 2008 Jun;8(4):243-52.

PMID:
18537548
7.
8.

Intracellular expression of inflammatory proteins S100A8 and S100A9 leads to epithelial-mesenchymal transition and attenuated aggressivity of breast cancer cells.

Cormier K, Harquail J, Ouellette RJ, Tessier PA, Guerrette R, Robichaud GA.

Anticancer Agents Med Chem. 2014 Jan;14(1):35-45.

PMID:
24041228
9.

Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer.

Hermani A, Hess J, De Servi B, Medunjanin S, Grobholz R, Trojan L, Angel P, Mayer D.

Clin Cancer Res. 2005 Jul 15;11(14):5146-52.

10.

RAGE-dependent regulation of calcium-binding proteins S100A8 and S100A9 in human THP-1.

Eggers K, Sikora K, Lorenz M, Taubert T, Moobed M, Baumann G, Stangl K, Stangl V.

Exp Clin Endocrinol Diabetes. 2011 Jun;119(6):353-7. doi: 10.1055/s-0030-1268426. Epub 2011 Apr 6.

PMID:
21472666
11.

S100A8, S100A9, and the S100A8/A9 complex in circulating blood are not associated with prostate cancer risk-A re-evaluation study.

Ludwig S, Stephan C, Lein M, Loening SA, Jung K.

Prostate. 2007 Sep 1;67(12):1301-7.

PMID:
17626245
12.

S100A8/A9 mRNA induction in an ex vivo model of endotoxin tolerance: roles of IL-10 and IFNγ.

Fontaine M, Planel S, Peronnet E, Turrel-Davin F, Piriou V, Pachot A, Monneret G, Lepape A, Venet F.

PLoS One. 2014 Jun 23;9(6):e100909. doi: 10.1371/journal.pone.0100909. eCollection 2014.

13.

S100A8/A9 induces apoptosis and inhibits metastasis of CasKi human cervical cancer cells.

Qin F, Song Y, Li Z, Zhao L, Zhang Y, Geng L.

Pathol Oncol Res. 2010 Sep;16(3):353-60. doi: 10.1007/s12253-009-9225-2. Epub 2009 Dec 3.

PMID:
19957061
14.

Smad4 loss is associated with fewer S100A8-positive monocytes in colorectal tumors and attenuated response to S100A8 in colorectal and pancreatic cancer cells.

Ang CW, Nedjadi T, Sheikh AA, Tweedle EM, Tonack S, Honap S, Jenkins RE, Park BK, Schwarte-Waldhoff I, Khattak I, Azadeh B, Dodson A, Kalirai H, Neoptolemos JP, Rooney PS, Costello E.

Carcinogenesis. 2010 Sep;31(9):1541-51. doi: 10.1093/carcin/bgq137. Epub 2010 Jul 9.

PMID:
20622003
15.

S100a8/a9 released by CD11b+Gr1+ neutrophils activates cardiac fibroblasts to initiate angiotensin II-Induced cardiac inflammation and injury.

Wu Y, Li Y, Zhang C, A X, Wang Y, Cui W, Li H, Du J.

Hypertension. 2014 Jun;63(6):1241-50. doi: 10.1161/HYPERTENSIONAHA.113.02843. Epub 2014 Apr 7.

16.

Identification of S100A8 and S100A9 as negative regulators for lymph node metastasis of gastric adenocarcinoma.

Choi JH, Shin NR, Moon HJ, Kwon CH, Kim GH, Song GA, Jeon TY, Kim DH, Kim DH, Park DY.

Histol Histopathol. 2012 Nov;27(11):1439-48. doi: 10.14670/HH-27.1439.

PMID:
23018243
17.

[Clinical significance of S100A8 and S100A9 expression in gastric cancer].

Hu Y, Fan B, Zhang LH, Cheng XJ, Niu ZJ, Ji JF.

Zhonghua Yi Xue Za Zhi. 2013 Nov 12;93(42):3369-74. Chinese.

PMID:
24418034
18.

S100A9 has a protective role in inflammation-induced skin carcinogenesis.

McNeill E, Hogg N.

Int J Cancer. 2014 Aug 15;135(4):798-808. doi: 10.1002/ijc.28725. Epub 2014 Jan 28.

19.

S100A8/A9 regulates MMP-2 expression and invasion and migration by carcinoma cells.

Silva EJ, Argyris PP, Zou X, Ross KF, Herzberg MC.

Int J Biochem Cell Biol. 2014 Oct;55:279-87. doi: 10.1016/j.biocel.2014.09.007. Epub 2014 Sep 16.

20.

Amyloid formation by the pro-inflammatory S100A8/A9 proteins in the ageing prostate.

Yanamandra K, Alexeyev O, Zamotin V, Srivastava V, Shchukarev A, Brorsson AC, Tartaglia GG, Vogl T, Kayed R, Wingsle G, Olsson J, Dobson CM, Bergh A, Elgh F, Morozova-Roche LA.

PLoS One. 2009;4(5):e5562. doi: 10.1371/journal.pone.0005562. Epub 2009 May 15.

Supplemental Content

Support Center